O'Hara Elaine 4/A

What Happened
Elaine O'Hara, Executive Vice President and Chief Strategy Officer of Novavax (NVAX), received a derivative grant of 177,500 shares (reported as a $0.00 acquisition) on March 2, 2026. The Form 4/A filed March 9, 2026 amends the originally reported exercise price for this option grant; all other reported details remain unchanged.

Key Details

• Transaction date: 2026-03-02 (period of report). Form 4 originally filed 2026-03-03; this is an amendment filed 2026-03-09 to correct the exercise price (Footnote F1).
• Reported transaction: Grant / award of 177,500 derivative shares (reported acquisition price $0.00 in the filing).
• Vesting: 1/4 vests one year after March 2, 2026; the remaining 3/4 vest in equal monthly installments over the following three years, subject to continued employment (Footnote F2).
• Shares owned after transaction: not specified in the supplied details of this filing.
• Filingtimeliness: Original Form 4 was filed March 3 (timely); this filing is an amendment to correct exercise-price reporting.

Context
This is an option-type award (derivative) rather than an open-market purchase or sale. Options vest over time and typically require payment of an exercise price to convert to common shares; because this filing amends the exercise price, check the amended Form 4 for the corrected strike price to understand potential future cash/tax implications. Option grants are a common part of executive compensation and do not themselves indicate immediate buying or selling of shares.